These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 19531695)

  • 1. Delirium in a patient with toxic flecainide plasma concentrations: the role of a pharmacokinetic drug interaction with paroxetine.
    Tsao YY; Gugger JJ
    Ann Pharmacother; 2009 Jul; 43(7):1366-9. PubMed ID: 19531695
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Changes in the QTc interval after administration of flecainide acetate, with and without coadministered paroxetine, in relation to cytochrome P450 2D6 genotype: data from an open-label, two-period, single-sequence crossover study in healthy Korean male subjects.
    Lim KS; Jang IJ; Kim BH; Kim J; Jeon JY; Tae YM; Yi S; Eum S; Cho JY; Shin SG; Yu KS
    Clin Ther; 2010 Apr; 32(4):659-66. PubMed ID: 20435235
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetic interaction of flecainide and paroxetine in relation to the CYP2D6*10 allele in healthy Korean subjects.
    Lim KS; Cho JY; Jang IJ; Kim BH; Kim J; Jeon JY; Tae YM; Yi S; Eum S; Shin SG; Yu KS
    Br J Clin Pharmacol; 2008 Nov; 66(5):660-6. PubMed ID: 18754843
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Duloxetine is both an inhibitor and a substrate of cytochrome P4502D6 in healthy volunteers.
    Skinner MH; Kuan HY; Pan A; Sathirakul K; Knadler MP; Gonzales CR; Yeo KP; Reddy S; Lim M; Ayan-Oshodi M; Wise SD
    Clin Pharmacol Ther; 2003 Mar; 73(3):170-7. PubMed ID: 12621382
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The relationship between clinical pharmacokinetics of aripiprazole and CYP2D6 genetic polymorphism: effects of CYP enzyme inhibition by coadministration of paroxetine or fluvoxamine.
    Azuma J; Hasunuma T; Kubo M; Miyatake M; Koue T; Higashi K; Fujiwara T; Kitahara S; Katano T; Hara S
    Eur J Clin Pharmacol; 2012 Jan; 68(1):29-37. PubMed ID: 21739267
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antidepressant drug interactions and the cytochrome P450 system. The role of cytochrome P450 2D6.
    Ereshefsky L; Riesenman C; Lam YW
    Clin Pharmacokinet; 1995; 29 Suppl 1():10-8; discussion 18-9. PubMed ID: 8846618
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Postoperative delirium indicating an adverse drug interaction involving the selective serotonin reuptake inhibitor, paroxetine?
    Stanford BJ; Stanford SC
    J Psychopharmacol; 1999; 13(3):313-7. PubMed ID: 10512094
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dose-dependent pharmacokinetic interaction of clozapine and paroxetine in an extensive metabolizer.
    Joos AA; König F; Frank UG; Kaschka WP; Mörike KE; Ewald R
    Pharmacopsychiatry; 1997 Nov; 30(6):266-70. PubMed ID: 9442550
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of cytochrome P4502D6 activity with paroxetine normalizes the ultrarapid metabolizer phenotype as measured by nortriptyline pharmacokinetics and the debrisoquin test.
    Laine K; Tybring G; Härtter S; Andersson K; Svensson JO; Widén J; Bertilsson L
    Clin Pharmacol Ther; 2001 Oct; 70(4):327-35. PubMed ID: 11673748
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CYP2D6 inhibition by selective serotonin reuptake inhibitors: analysis of achievable steady-state plasma concentrations and the effect of ultrarapid metabolism at CYP2D6.
    Lam YW; Gaedigk A; Ereshefsky L; Alfaro CL; Simpson J
    Pharmacotherapy; 2002 Aug; 22(8):1001-6. PubMed ID: 12173784
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Delirium associated with paroxetine in an elderly depressive patient: a case report.
    Wakeno M; Okugawa G; Takekita Y; Kato M; Fukuda T; Yamashita M; Hosoi Y; Azuma J; Kinoshita T
    Pharmacopsychiatry; 2007 Sep; 40(5):199-200. PubMed ID: 17874351
    [No Abstract]   [Full Text] [Related]  

  • 12. Determinants of interindividual variability and extent of CYP2D6 and CYP1A2 inhibition by paroxetine and fluvoxamine in vivo.
    Ozdemir V; Naranjo CA; Shulman RW; Herrmann N; Sellers EM; Reed K; Kalow W
    J Clin Psychopharmacol; 1998 Jun; 18(3):198-207. PubMed ID: 9617978
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Interaction between paroxetine and clomipramine as a possible reason for admission to a department of internal medicine].
    Skjelbo EF; Brøsen K
    Ugeskr Laeger; 1998 Sep; 160(39):5665-6. PubMed ID: 9771062
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Paroxetine potentiates the central nervous system side effects of perphenazine: contribution of cytochrome P4502D6 inhibition in vivo.
    Ozdemir V; Naranjo CA; Herrmann N; Reed K; Sellers EM; Kalow W
    Clin Pharmacol Ther; 1997 Sep; 62(3):334-47. PubMed ID: 9333110
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetic model incorporating mechanism-based inactivation of CYP2D6 can explain both non-linear kinetics and drug interactions of paroxetine.
    Mikami A; Ohtani H; Hori S; Sawada Y
    Int J Clin Pharmacol Ther; 2013 May; 51(5):374-82. PubMed ID: 23357843
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reboxetine and cytochrome P450--comparison with paroxetine treatment in humans.
    Kuhn UD; Kirsch M; Merkel U; Eberhardt AM; Wenda B; Maurer I; Härtter S; Hiemke C; Volz HP; Balogh A
    Int J Clin Pharmacol Ther; 2007 Jan; 45(1):36-46. PubMed ID: 17256449
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacological interaction between 3,4-methylenedioxymethamphetamine (ecstasy) and paroxetine: pharmacological effects and pharmacokinetics.
    Farré M; Abanades S; Roset PN; Peiró AM; Torrens M; O'Mathúna B; Segura M; de la Torre R
    J Pharmacol Exp Ther; 2007 Dec; 323(3):954-62. PubMed ID: 17890444
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CYP2D6 inhibition by fluoxetine, paroxetine, sertraline, and venlafaxine in a crossover study: intraindividual variability and plasma concentration correlations.
    Alfaro CL; Lam YW; Simpson J; Ereshefsky L
    J Clin Pharmacol; 2000 Jan; 40(1):58-66. PubMed ID: 10631623
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Altering metabolic profiles of drugs by precision deuteration: reducing mechanism-based inhibition of CYP2D6 by paroxetine.
    Uttamsingh V; Gallegos R; Liu JF; Harbeson SL; Bridson GW; Cheng C; Wells DS; Graham PB; Zelle R; Tung R
    J Pharmacol Exp Ther; 2015 Jul; 354(1):43-54. PubMed ID: 25943764
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CYP2D6 genotype affects age-related decline in flecainide clearance: a population pharmacokinetic analysis.
    Doki K; Homma M; Kuga K; Aonuma K; Kohda Y
    Pharmacogenet Genomics; 2012 Nov; 22(11):777-83. PubMed ID: 22941032
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.